Loading stock data…
Collegium Pharmaceutical (COLL)
$36.20+0.22 (+0.61%)
Market ClosedLast close Jun 30
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Collegium Pharmaceutical, Inc. in the Healthcare sector is trading at $36.20 with a market capitalization of $1.1B. Wall Street consensus targets $54.33 (6 analysts), implying a +50.1% move over the next 12 months. The stock is currently 29% below its 52-week high of $50.79, remaining 7.6% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +50.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $193.52M↓ | $205.45M↓ | $209.36M↑ | $188.00M↑ | $177.76M |
| Gross Profit | $117.25M↓ | $128.38M↓ | $129.17M↑ | $108.38M↑ | $97.32M |
| Operating Income | $30.90M↓ | $60.74M↓ | $62.07M↑ | $34.75M↑ | $20.90M |
| Net Income | $14.50M↓ | $16.96M↓ | $31.51M↑ | $11.98M↑ | $2.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.99%
Volume
Today's trading volume
331,078
Recent News
Bull of the Day: Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 of Wall Street’s Favorite Stocks We Approach with Caution
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
2 Reasons to Sell COLL and 1 Stock to Buy Instead
Shareholders of Collegium Pharmaceutical would probably like to forget the past six months even happened. The stock dropped 36.3% and now trades at $30.47. This might have investors contemplating their next move.
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness
Collegium Pharmaceutical (COLL) has drawn investor attention after recent share price pressure, with the stock down 5% over the past day and 7% over the past week, extending weakness seen over the past month. See our latest analysis for Collegium Pharmaceutical. At the current share price of $31.78, Collegium Pharmaceutical’s recent slide, with the share price return down 20.53% over 90 days and 30.20% year to date, contrasts with its 8.43% one year total shareholder return and 50.90% three...